Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

被引：3
|
作者：
Gouda, M. A. [1 ]
Hu, M. I. [2 ]
Cabanillas, M. E. [2 ]
Wu, J. [3 ,4 ]
Meric-Bernstam, F. [1 ]
Subbiah, V. [1 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
[5] Sarah Cannon Res Inst, Early Phase Drug Dev, Nashville, TN 37203 USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 10期
基金：
美国国家卫生研究院;
关键词：
CACHEXIA; PATHWAY;
D O I：
10.1016/j.annonc.2023.07.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：946 / 948
页数：3
相关论文
共 50 条
  • [41] The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi kinase inhibitors
    Rahal, Rami
    Evans, Erica K.
    Hu, Wei
    Maynard, Michelle
    Fleming, Paul
    DiPietro, Lucian
    Kim, Joseph L.
    Sheets, Michael P.
    Wilson, Doug P.
    Wilson, Kevin J.
    Stransky, Nicolas
    Brubaker, Jason D.
    Guzi, Timothy
    Kohl, Nancy E.
    Lengauer, Christoph
    CANCER RESEARCH, 2016, 76
  • [42] Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer
    Wan, R.
    Duan, J.
    Wang, Z.
    Lin, L.
    Li, W.
    Jie, W.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
  • [43] Non-adenocarcinoma histology in patients with RET plus lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry
    Marinello, A.
    Massa, G.
    Rotow, J.
    Bote De Cabo, H.
    Monnet, I.
    Guisier, F.
    Duruisseaux, M.
    Benitez Montanez, J. C.
    Raimbourg, J.
    Costa, J.
    Tagliamento, M.
    Feng, J.
    Di Federico, A.
    Metro, G.
    Citarella, F.
    Tabbo, F.
    Lindsay, C.
    Iranzo Gomez, P.
    Besse, B.
    Aldea, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S824 - S824
  • [44] Aberrant SOX10 and RET expressions in patients with Hirschsprung disease
    Gunadi
    Amadeus, Verrell Christopher
    Utami, Fadila Dyah Trie
    Halim, Fiqih Vidiantoro
    Novebri, Nabilah Anisa
    Hanggoro, Rahaditya Alrasyidi
    Lestari, Avinindita Nura
    Iskandar, Kristy
    Dwihantoro, Andi
    Purnomo, Eko
    BMC PEDIATRICS, 2024, 24 (01)
  • [45] Aberrant SOX10 and RET expressions in patients with Hirschsprung disease
    Verrell Christopher Gunadi
    Fadila Dyah Trie Amadeus
    Fiqih Vidiantoro Utami
    Nabilah Anisa Halim
    Rahaditya Alrasyidi Novebri
    Avinindita Nura Hanggoro
    Kristy Lestari
    Andi Iskandar
    Eko Dwihantoro
    BMC Pediatrics, 24
  • [46] A Potent, VEGFR2-Sparing RET Kinase Inhibitor for Treating Patients with RET-Dependent Lung Cancers
    Rothenberg, Stephen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1452 - S1452
  • [47] Dissecting mechanisms of resistance to new generation selective RET inhibitors in NSCLC
    Esposito, D.
    Ascione, C. M.
    Belli, S.
    Servetto, A.
    Formisano, L.
    Bianco, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S149 - S149
  • [48] The development of a potent, KDRNEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
    Brandhuber, B.
    Haas, J.
    Tuch, B.
    Ebata, K.
    Bouhana, K.
    McFaddin, E.
    Williams, L.
    Winski, S.
    Brown, E.
    Burkhard, M.
    Nanda, N.
    Hamor, R.
    Sullivan, F.
    Hanson, L.
    Morales, T.
    Vigers, G.
    Wallace, R. D.
    Blake, J.
    Andrews, S.
    Rothenberg, S. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S144 - S144
  • [49] Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
    Wan, Rui
    Li, Weihua
    Wang, Zhijie
    Zhong, Jia
    Lin, Lin
    Duan, Jianchun
    Wang, Jie
    HELIYON, 2024, 10 (02)
  • [50] Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
    Lin, J. J.
    Liu, S., V
    McCoach, C. E.
    Zhu, V. W.
    Tan, A. C.
    Yoda, S.
    Peterson, J.
    Do, A.
    Prutisto-Chang, K.
    Dagogo-Jack, I
    Sequist, L., V
    Wirth, L. J.
    Lennerz, J. K.
    Hata, A. N.
    Mino-Kenudson, M.
    Nardi, V
    Ou, S-H, I
    Tan, D. S-W
    Gainor, J. F.
    ANNALS OF ONCOLOGY, 2020, 31 (12) : 1725 - 1733
12345